Ketamine (Ketaset)

Ketamine has served as a cornerstone of small animal anesthesia for decades, providing reliable dissociative anesthesia for guinea pigs and other exotic species through a unique mechanism that distinguishes it from other injectable anesthetics. This phencyclidine derivative produces a cataleptic state characterized by profound analgesia, sedation, and amnesia while maintaining certain protective reflexes better than agents producing true general anesthesia. Exotic veterinarians routinely employ ketamine, typically in combination with other agents, for guinea pig procedures ranging from simple chemical restraint to surgical anesthesia.

The mechanism of action of ketamine involves antagonism of N-methyl-D-aspartate receptors in the central nervous system, blocking the excitatory neurotransmitter glutamate and producing the characteristic dissociative state. This NMDA receptor blockade differs fundamentally from the mechanisms of other anesthetics, contributing to ketamine's unique clinical profile including preserved respiratory drive and pharyngeal reflexes at moderate doses. The dissociative state separates the patient from their environment, providing immobility and apparent unawareness even though EEG patterns differ from those seen with conventional anesthetics.

Ketamine is available as an injectable solution typically at concentrations of one hundred milligrams per milliliter, administered most commonly via intramuscular injection in guinea pig practice. The drug can also be given subcutaneously or intravenously depending on clinical circumstances. Because ketamine alone produces poor muscle relaxation and may cause undesirable emergence behavior, it is almost always combined with sedatives or muscle relaxants such as midazolam, xylazine, or dexmedetomidine in guinea pig protocols.

The safety profile of ketamine in guinea pigs is generally favorable when appropriate combinations and doses are employed, though the drug produces different physiological effects than other anesthetics. Cardiovascular stimulation, increased salivation, and maintenance of protective reflexes distinguish ketamine from agents like alfaxalone or propofol. Understanding these unique characteristics allows veterinarians to employ ketamine safely and effectively in guinea pig patients requiring anesthesia for various procedures.

The primary indication for ketamine in guinea pig medicine is chemical restraint and anesthesia induction as part of combination protocols. Ketamine alone rarely provides adequate surgical anesthesia due to insufficient muscle relaxation and potential for undesirable movement, so combination with agents like midazolam or alpha-2 agonists is standard practice. These combinations produce more complete anesthesia with better muscle relaxation than ketamine monotherapy while requiring lower individual drug doses.

Short surgical procedures may be performed under ketamine combination anesthesia when the anticipated duration falls within the effective period of the injectable protocol. Minor wound repair, abscess drainage, small tumor excision, and similar procedures of fifteen to thirty minutes duration can often be accomplished under ketamine-based protocols without requiring transition to inhalant anesthesia. The duration of effective anesthesia depends on the specific combination used and individual patient factors.

Diagnostic procedures requiring patient immobilization represent another common application of ketamine combinations in guinea pig practice. Radiographic imaging, detailed physical examination of fractious patients, and diagnostic sample collection can be accomplished with the reliable immobilization provided by ketamine-based sedation or light anesthesia. Lower doses may suffice for sedation purposes compared to surgical anesthesia requirements.

Induction of anesthesia before transition to inhalant maintenance represents an important ketamine application, allowing smooth progression from injectable to inhalant agents for extended procedures. Ketamine combination induction avoids the respiratory irritation of mask or chamber induction with inhalants alone while providing a relaxed, manageable patient for establishment of inhalant delivery. Many exotic veterinarians prefer injectable induction for the predictability and reduced patient stress compared to direct inhalant induction.

Emergency situations may warrant ketamine use when rapid chemical restraint is needed for stabilization or urgent procedures. The intramuscular route produces reliable effects without requiring intravenous access, which can be technically challenging in compromised guinea pig patients. Emergency ketamine administration must be followed by appropriate monitoring and supportive care, as critically ill patients carry elevated anesthetic risk regardless of agent selection.

Ketamine dosing in guinea pigs depends critically on the combination agents employed, as the drug is rarely used as a sole anesthetic agent. When combined with midazolam, typical ketamine doses range from twenty to forty milligrams per kilogram, with the higher end of this range needed when profound anesthesia is required. Ketamine-medetomidine or ketamine-dexmedetomidine combinations allow lower ketamine doses of five to fifteen milligrams per kilogram due to the potent sedative contribution of the alpha-2 agonist. Accurate body weight determination using a gram-scale is essential for safe dosing.

Intramuscular administration represents the most common route for ketamine delivery in guinea pig practice, offering reliable absorption and practical administration in small patients where intravenous access may be challenging. Injection into the quadriceps or epaxial muscles provides appropriate absorption, with onset typically occurring within five to fifteen minutes depending on the combination used. Large volumes may be divided between multiple injection sites to reduce discomfort.

Subcutaneous administration offers an alternative when intramuscular injection is problematic, though absorption may be slower and less predictable. Higher doses may be required to achieve equivalent effects compared to intramuscular administration. The subcutaneous route is less commonly selected for ketamine in guinea pigs but remains a viable option in appropriate circumstances.

Intravenous administration produces the most rapid onset and allows titration to effect but requires technical skill in small patients. When intravenous access is established for other reasons, ketamine may be administered through this route at lower doses than required for intramuscular injection. Rapid intravenous injection should be avoided, with slow administration over thirty to sixty seconds preferred.

Duration of effect following ketamine combination administration varies based on the specific agents used, doses administered, and individual patient factors. Ketamine-midazolam combinations typically provide thirty to sixty minutes of effective anesthesia, while ketamine combinations with alpha-2 agonists may provide longer duration. Procedures anticipated to exceed the effective duration require either supplemental dosing or transition to inhalant maintenance.

Recovery from ketamine anesthesia tends to be longer than from some alternatives, with complete return to normal behavior potentially requiring one to four hours depending on the protocol used. Recovery quality may include periods of disorientation or ataxia, particularly if alpha-2 antagonists are not used to reverse that component of combination protocols. Guinea pigs should be monitored throughout recovery in warm, quiet environments until fully ambulatory and behaviorally normal.

Cardiovascular stimulation distinguishes ketamine from other anesthetics that typically produce cardiovascular depression. Ketamine increases heart rate, blood pressure, and myocardial oxygen demand through sympathetic nervous system activation. While this cardiovascular profile may be advantageous in some situations, it represents a concern in patients with cardiac disease or hypertension. The cardiovascular effects of combination protocols depend on both ketamine and the co-administered agents, with alpha-2 agonists producing cardiovascular depression that may offset ketamine's stimulatory effects.

Increased salivation and respiratory secretions commonly occur during ketamine anesthesia, potentially complicating airway management in small patients. Pre-treatment with anticholinergic agents like glycopyrrolate can reduce these secretions when they are anticipated to be problematic. Guinea pigs showing excessive salivation during ketamine anesthesia should be positioned to prevent aspiration, and suction should be available if needed.

Maintained protective reflexes including pharyngeal and laryngeal reflexes persist during ketamine anesthesia more than with other agents, providing some protection against aspiration. However, these reflexes may be obtunded at deeper anesthetic planes or when ketamine is combined with other agents that suppress reflexes. Reliance on reflex protection is not appropriate, and standard aspiration precautions should be maintained.

Muscle rigidity and spontaneous movement may occur during ketamine anesthesia, particularly when the drug is used without adequate muscle relaxant co-administration. These effects limit ketamine's usefulness as a sole agent and motivate the universal recommendation for combination protocols. Addition of midazolam or alpha-2 agonists significantly improves muscle relaxation and reduces unwanted movement.

Emergence phenomena including vocalization, disorientation, and hyperexcitability may occur during recovery from ketamine anesthesia. These emergence effects are generally mild in guinea pigs compared to some other species but can be distressing to observe. Recovery in quiet, dark environments with minimal stimulation helps reduce emergence problems. Alpha-2 agonist reversal with atipamezole or yohimbine may accelerate recovery but does not eliminate ketamine effects that must undergo metabolic clearance.

Cardiovascular disease represents a significant contraindication to ketamine use given the drug's sympathomimetic effects that increase myocardial workload and oxygen demand. Guinea pigs with known cardiac conditions, particularly those with hypertrophic changes or valve disease, may not tolerate the cardiovascular stimulation produced by ketamine. Alternative anesthetics with cardiovascular depressant rather than stimulant profiles may be more appropriate for these patients.

Intracranial pathology including head trauma, space-occupying lesions, or conditions with elevated intracranial pressure contraindicates ketamine use. The drug increases cerebral blood flow and intracranial pressure, potentially worsening outcomes in patients with intracranial disease. Alternative anesthetics without these effects should be selected for guinea pigs with known or suspected brain pathology.

Conditions involving increased intraocular pressure, including glaucoma, represent relative contraindications to ketamine due to the drug's effects on ocular pressure. Guinea pigs requiring anesthesia for ophthalmic procedures or those with known ocular hypertension may be better served by alternative agents. The clinical significance of ketamine's ocular pressure effects in guinea pigs specifically is not extensively documented.

Respiratory disease does not necessarily contraindicate ketamine, as the drug maintains respiratory drive better than many alternatives. However, increased respiratory secretions produced by ketamine may complicate management of patients with existing airway disease. Anticholinergic pre-treatment can mitigate secretion increases. Overall anesthetic risk assessment considers all patient factors rather than ketamine-specific contraindications alone.

Known hypersensitivity to ketamine contraindicates use, though allergic reactions to this agent are rare. Previous adverse reactions should be documented and their nature determined, as many perceived reactions actually represent normal pharmacological effects of dissociative anesthesia rather than hypersensitivity.

Benzodiazepines like midazolam represent the most common ketamine combination in guinea pig practice, producing synergistic effects that improve anesthetic quality while allowing dose reduction of both agents. Midazolam provides muscle relaxation, sedation, and anxiolysis that complement ketamine's analgesic and dissociative effects. This interaction is intentionally exploited rather than avoided, forming the basis of standard ketamine-midazolam protocols.

Alpha-2 adrenergic agonists including dexmedetomidine and medetomidine combine with ketamine to produce profound sedation and analgesia with improved muscle relaxation. These combinations allow significant ketamine dose reduction while providing reversibility through alpha-2 antagonist administration. The cardiovascular effects of alpha-2 agonists somewhat offset ketamine's cardiovascular stimulation, though the combined effects remain complex and require monitoring.

Opioid analgesics may be added to ketamine protocols to enhance analgesia, particularly for painful procedures. Butorphanol, buprenorphine, or other opioids contribute to multimodal analgesia without adverse pharmacokinetic interactions with ketamine. The analgesic synergy allows better pain control than either agent class alone.

Non-steroidal anti-inflammatory drugs do not interact adversely with ketamine and may be administered as part of comprehensive perioperative pain management. Meloxicam can be given before or after ketamine anesthesia according to the veterinarian's analgesic protocol. Timing relative to anesthesia depends on procedural considerations rather than drug interactions.

Vitamin C supplementation should continue throughout the perioperative period in guinea pig patients receiving ketamine, as with any anesthetic agent. The stress of anesthesia may increase vitamin C requirements. No interaction exists between ketamine and vitamin C, and oral supplementation resumes when normal eating returns following anesthetic recovery.

Pre-anesthetic evaluation establishes patient suitability for ketamine anesthesia and identifies conditions warranting alternative agent selection. Physical examination should assess cardiovascular status, respiratory function, and overall health. Body weight determination enables accurate dose calculation. Pre-anesthetic laboratory testing, when available, may identify abnormalities affecting anesthetic choices or patient preparation.

Fasting guidelines for guinea pigs prior to ketamine anesthesia follow the same principles as for other anesthetics. Prolonged fasting is contraindicated in this species due to continuous hindgut fermentation, hypoglycemia risk, and susceptibility to hepatic lipidosis. Most exotic veterinarians recommend either no fasting or brief food withholding of one to two hours maximum. The maintenance of protective reflexes during ketamine anesthesia does not eliminate aspiration risk sufficiently to justify extended fasting.

Monitoring during ketamine anesthesia should assess cardiovascular function given the drug's stimulatory effects, as well as respiratory status and temperature. Heart rate monitoring may show elevation from ketamine's sympathomimetic effects, and this should be distinguished from inadequate anesthesia or pain. Respiratory rate and pattern assessment confirms adequate ventilation, while temperature monitoring identifies hypothermia requiring intervention.

Anticholinergic pre-treatment with glycopyrrolate or atropine may be considered to reduce excessive salivation associated with ketamine administration. The decision to use anticholinergics balances secretion management against potential adverse effects including heart rate elevation. Not all patients require anticholinergic pre-treatment, and the decision is made individually based on anticipated procedure, patient factors, and veterinarian preference.

Recovery monitoring should continue until guinea pigs are fully ambulatory and behaviorally normal, which may require one to four hours depending on the protocol used. Quiet, warm, low-stimulation recovery environments help reduce emergence phenomena. Temperature support prevents hypothermia. Food access encourages return to eating, which is important for preventing gastrointestinal complications. Guinea pigs not eating within several hours of apparent recovery may require assisted feeding.

Ketamine storage must comply with controlled substance regulations applicable in the jurisdiction where it is used. The drug is classified as a Schedule III controlled substance in the United States and carries similar classification in many other countries. Secure storage in locked cabinets with access limited to authorized personnel is legally required. Records of ketamine use, including quantities administered and patient identification, must be maintained according to regulatory requirements.

The drug itself is stable at room temperature when protected from light and stored in its original container. Expiration dates should be observed, and expired ketamine disposed of according to controlled substance disposal regulations. The one hundred milligram per milliliter concentration common in veterinary formulations provides practical volumes for guinea pig dosing while requiring attention to accurate measurement.

Dose preparation requires accurate volume measurement using appropriately sized syringes. The relatively high concentration of veterinary ketamine formulations means that guinea pig doses, even at twenty to forty milligrams per kilogram, involve manageable volumes. Combination protocols require preparation of both ketamine and co-administered agents, which may be mixed in the same syringe when compatible or administered separately as indicated.

Controlled substance documentation requirements apply to all ketamine use, including detailed records of quantities withdrawn, patients treated, doses administered, and any wastage. Regulatory inspections may verify compliance with documentation and storage requirements. Veterinary facilities using ketamine must maintain systems ensuring regulatory compliance in addition to clinical safety.

Guinea pig breed does not significantly influence ketamine pharmacology or dosing requirements, as all breeds share similar physiological characteristics affecting drug handling. Per-kilogram dosing guidelines apply regardless of breed, with individual body weight being the primary determinant of appropriate dose. No breed-specific adjustments to ketamine protocols are recommended based on current evidence.

Hairless guinea pig breeds including Skinny pigs require enhanced temperature support during ketamine anesthesia due to accelerated heat loss without insulating fur. Active warming measures should be implemented from induction through complete recovery. The extended recovery period typical of ketamine protocols increases the duration during which temperature support is needed in these breeds.

Long-haired guinea pig breeds may require coat management for injection site access and monitoring equipment placement. These practical considerations affect procedure execution without changing ketamine dosing or pharmacokinetics. Long coat provides some insulation during the anesthetic period, which may help maintain temperature compared to short-haired or hairless guinea pigs.

Body size variation among guinea pigs affects practical aspects of ketamine administration, including injection volume and syringe selection. Smaller guinea pigs require careful attention to accurate dose measurement, as the potent concentration of ketamine makes small volume errors potentially significant. Larger guinea pigs may receive larger absolute doses that are easier to measure accurately while following the same per-kilogram guidelines.

Alfaxalone represents the primary alternative injectable anesthetic to ketamine for guinea pig procedures, offering a neurosteroid option with different pharmacological characteristics. Alfaxalone produces true general anesthesia rather than dissociative anesthesia and may provide better muscle relaxation than ketamine combinations. Recovery from alfaxalone is generally faster than from ketamine-based protocols. Selection between these agents depends on procedure requirements, patient factors, and veterinarian experience.

Inhalant anesthetics including isoflurane and sevoflurane provide maintenance anesthesia following ketamine-based induction or serve as primary agents when injectable anesthesia is not preferred. Ketamine combinations provide smooth induction followed by inhalant maintenance for extended procedures, combining the benefits of each approach. Transition from injectable to inhalant anesthesia requires appropriate timing and equipment.

Medetomidine and dexmedetomidine represent important adjuncts to ketamine that improve anesthetic quality through profound sedation, analgesia, and muscle relaxation. These alpha-2 agonists allow significant ketamine dose reduction while providing reversibility through antagonist administration. Ketamine-medetomidine or ketamine-dexmedetomidine combinations are widely used alternatives to ketamine-midazolam protocols.

Midazolam remains the most commonly used ketamine adjunct in guinea pig practice due to availability, safety, and reliability. The ketamine-midazolam combination provides good working anesthesia for many procedures while avoiding the more profound cardiovascular effects of alpha-2 agonist combinations. Selection among ketamine combinations considers procedure requirements, patient status, and desired recovery characteristics.